SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001683168-24-004367
Filing Date
2024-06-20
Accepted
2024-06-20 17:00:11
Documents
15
Period of Report
2024-06-14
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO CURRENT REPORT cns_8ka1.htm   iXBRL 8-K/A 30857
2 ARENTFOX SCHIFF LLP LEGAL OPINION cns_ex0501.htm EX-5.1 16682
3 GRAPHIC image_001.jpg GRAPHIC 6363
  Complete submission text file 0001683168-24-004367.txt   238169

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20240614.xsd EX-101.SCH 3018
5 XBRL LABEL FILE cnsp-20240614_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE cnsp-20240614_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT cns_8ka1_htm.xml XML 3918
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39126 | Film No.: 241057268
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)